NIH Pushes Ahead With First COVID-19 Combo: Remdesivir Plus Lilly’s Olumiant

Adaptive Trial Skips Monotherapy Arm, Uses Factorial Design

 
• By Andrew McConaghie
BETHESDA, MD - JUNE 29, 2019: NIH NATIONAL INSTITUTES OF HEALTH sign emblem seal on gateway center entrance building at NIH campus
The NIH's NIAID is leading an international consortium in the second ACTT study

More from COVID-19

More from Scrip